Dostarlimab effectively eliminates the need for surgery in patients with advanced mismatch repair-deficient (dMMR) tumors, ...

Onc.AI, a digital health company developing advanced AI-driven clinical management solutions for oncology, today announced that findings from a recent collaboration with global biopharma company GSK ...

A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for ...

Bret Hulick was in his second year of medical school at LECOM in Erie, analyzing the case of a 24-year-old colon cancer patient. The patient had to choose ...

Bret Hulick was in his second year of medical school at LECOM in Erie, analyzing the case of a 24-year-old colon cancer ...

Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose administration for the first patient in a Phase 2 trial for its experimental drug ...

Karen Stephens was later diagnosed with bowel cancer and has urged others not to risk their lives because of 'pride' ...

A phase 1/2 trial (NCT06065462) is currently underway to evaluate the safety and efficacy of PP2A inhibition with LB-100 plus dostarlimab-gxly (Jemperli) in recurrent ovarian clear cell carcinoma. 3 ...

Biocartis announced the launch of its real-time quantitative polymerase chain reaction assay to detect POLE and POLD1 mutations in endometrial cancer. Biocartis has launched a fully automated, ...

13,15,16 OVERALL SURVIVAL BENEFIT WITH DOSTARLIMAB IN RUBY PART 1 WAS A HIGH POINT OF 2024 There was an early signal from the RUBY Part 1 interim data in 2023 that the observed PFS benefit may ...